SCHEMBL20536264

SCHEMBL20536264

Nc1cc(Cl)c(OCc2ccc(F)cc2)cc1N

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 5/20 0.49
IDO1 P14902 2/20 0.44
AGXT P21549 2/20 0.44
SLC6A4 P31645 2/20 0.44
PPARA Q07869 1/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
MAPT P10636 2/20 0.43
SLC6A2 P23975 1/20 0.43
SLC6A3 Q01959 1/20 0.43
APP P05067 1/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
CISD1 Q9NZ45 1/20 0.42
MAPK14 Q16539 1/20 0.41
LMNA P02545 1/20 0.41
POLB P06746 1/20 0.41
STAT3 P40763 1/20 0.41
HTT P42858 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30792312 0.90 MAOB (0.46) MAOBIDO1AGXTSLC6A4PPARA
SCHEMBL20535823 0.86 CCR5 (0.49) MAOBIDO1AGXTSLC6A4MAPT
SCHEMBL20535507 0.83 GAA (0.51) MAOBNPC1RAB9AMAPTAPP
SCHEMBL20535609 0.83 MAOB (0.55) MAOBIDO1AGXTLMNA
SCHEMBL31193398 0.82 MAOB (0.56) MAOBIDO1AGXTSLC6A4PPARA
SCHEMBL3320471 0.82 MAOB (0.56) MAOBIDO1AGXTSLC6A4PPARA
SCHEMBL20535544 0.82 PTGES (0.47) MAOBPPARANPC1RAB9AMAPT
SCHEMBL17543219 0.81 MRGPRX4 (0.47) MAOBIDO1AGXTCCR5
SCHEMBL10719896 0.79 RAB9A (0.46) MAOBSLC6A4PPARANPC1RAB9A
SCHEMBL20536404 0.78 NPC1 (0.46) PPARANPC1RAB9AMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11339144-B2 Heteroaryl Rheb inhibitors and uses thereof NAVITOR PHARMACEUTICALS, INC. (US) 2022-05-24 US disclosed
US-11339144-B2 Heteroaryl Rheb inhibitors and uses thereof NAVITOR PHARMACEUTICALS, INC. (US) 2022-05-24 US disclosed
US-20210238165-A1 HETEROARYL RHEB INHIBITORS AND USES THEREOF NAVITOR PHARMACEUTICALS, INC. 2021-08-05 US disclosed
US-20210238165-A1 HETEROARYL RHEB INHIBITORS AND USES THEREOF NAVITOR PHARMACEUTICALS, INC. 2021-08-05 US disclosed
WO-2018191146-A1 HETEROARYL RHEB INHIBITORS AND USES THEREOF NAVITOR PHARMACEUTICALS, INC. (US) 2018-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210238165-A1 HETEROARYL RHEB INHIBITORS AND USES THEREOF RHEB, KRAS, NRAS MAOB 491/4885IDO1 2311/4885AGXT 3767/4885
US-11339144-B2 Heteroaryl Rheb inhibitors and uses thereof RHEB, GDI2, KRAS MAOB 1112/4885IDO1 3778/4885AGXT 2551/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.